Kidney Failure Treatment with Statins: Exploring Benefits, Drawbacks, and Consequences
In the management of chronic kidney disease (CKD), the use of statins, a group of medications that lower cholesterol levels, presents both potential benefits and risks.
Benefits
Statins have been shown to significantly reduce all-cause mortality and major adverse cardiovascular events in patients with mild to moderate CKD. By lowering atherogenic lipoproteins and exerting anti-inflammatory and plaque-stabilizing effects, statins offer important cardiovascular protection, as CKD amplifies cardiovascular mortality.
Additionally, statins may stabilize kidney function and reduce the risk of contrast-induced nephropathy, and could potentially slow CKD progression in select populations. They are considered first-line therapy to prevent atherosclerotic cardiovascular disease (ASCVD), which is common in CKD patients, improving overall cardiovascular outcomes.
Risks
However, in patients with advanced CKD or kidney failure, high-dose statins can increase risks such as hematuria (blood in urine) and the serious condition rhabdomyolysis—a severe muscle damage that can worsen kidney function. The risk of rhabdomyolysis, although relatively low in the general population, is higher in those with impaired renal function, and it is a major cause of statin intolerance and discontinuation.
Moreover, statins can slightly increase blood sugar levels, raising the risk of developing type 2 diabetes, especially in those already at risk. However, the benefits of statins in managing cholesterol levels often outweigh this risk.
The safety of statins depends on factors such as the statin type, dose, renal function, and potential drug interactions, calling for careful individualized prescribing and monitoring.
Summary
In the case of kidney failure, doctors may prescribe statins to manage cholesterol levels if the patient also has heart disease. Rhabdomyolysis can cause kidney damage or failure, permanent disability, and death. It is crucial for doctors to carefully dose, monitor, and assess the risks and benefits when prescribing statins to people with kidney failure.
Individuals experiencing symptoms of rhabdomyolysis, such as dark urine, severe muscle pain, muscle weakness, fatigue, muscle inflammation, confusion, nausea, vomiting, irregular heartbeat, and more, should contact a doctor urgently.
[1] Baigent C, Keech A, Kearns R et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. BMJ 2005; 331: 1023-1029. [2] Kjekshus J, Pedersen TR, Bangstad B et al. Cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials of statin therapy. J Am Coll Cardiol 2008; 52: 1401-1411. [3] National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines and Clinical Practice Recommendations for the Prevention and Treatment of Cholesterol Abnormalities in Chronic Kidney Disease. Am J Kidney Dis 2013; 61(6 Suppl 1): S1-S143. [4] Grundy SM, Brewer HB, Cleeman JI et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ASPC/NLA/IP ACC/AHA/AACVPR/AAPA/ABC/ASPC/NLA/IP ACC/AHA/TCT Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1082-e1156.
